Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Purpose: Biochemical markers of both osteoblast and osteoclast activity are elevated in men with osteoblastic metastases from prostate cancer. Androgen deprivation therapy (ADT), the mainstay of therapy for advanced prostate cancer, increases markers of osteoblast and osteoclast activity, even in the absence of bone metastases. Little is known about the relative contributions of ADT and skeletal metastases to elevated bone turnover in men with prostate cancer. Experimental Design: To evaluate the relative contributions of ADT and skeletal metastases to osteoblast and osteoclast activity, we performed a cross-sectional study in three groups of men with advanced prostate cancer: (a) hormone-naïve men without bone metastases; (b) castrate men without bone metastases; and (c) castrate men with bone metastases. The primary study end points were serum levels of bone-specific alkaline phosphatase (BSAP), a marker of osteoblast activity, and N-telopeptide (NTX), a marker of osteoclast activity. Results: Serum levels of both BSAP and NTX were significantly higher in groups of castrate men (groups 2 and 3) than in hormone-naïve men (group 1; P < 0.01 for all comparisons). Among castrate men, serum BSAP was significantly higher in men with bone metastases than in men without bone metastases (P = 0.01). In contrast, serum levels of NTX were similar in groups 2 and 3 (P = 0.33). Conclusions: The unintended effects of ADT on the skeleton are sufficient to explain increased osteoclast activity in castrate men with bone metastases. These results may have important implications for the optimal timing and schedule of osteoclast-targeted therapy in men with advanced prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [45]
Citations
Cites
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656 · cited 1×
“every 3 weeks) decreased significantly the risk of skeletal related events, a composite end point consisting of radiation to bone, fractures, spinal cord compression, change in antineoplastic therapy to treat bone pain, and surgery to bone (14).”
BackgroundBubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977 · cited 1×
“Group 3 included men with stable disease and men with progressive, androgenindependent disease, by PSA Working Group criteria (13).”
BackgroundSelf-citationIntravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877 · cited 1×
“once) decreased markers of osteoclast activity by about 60% and increased bone mineral density (15).”
BackgroundPamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Self-citationSMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Self-citationMarkers of bone turnover for the management of patients with bone metastases from prostate cancer
Garnero, P., Buchs, N., Zekri, J., Rizzoli, R., Coleman, R. E., & Delmas, P. D. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1012 · Cited by 238
BERRUTI, A., DOGLIOTTI, L., BITOSSI, R., FASOLIS, G., GORZEGNO, G., BELLINA, M., TORTA, M., PORPIGLIA, F., FONTANA, D., & ANGELI, A. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67149-2 · Cited by 212
Costa, L., Demers, L. M., Oliveira, A. G., Schaller, J. A., Costa, E. B., de Moura, M. C., & Lipton, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.850 · Cited by 193
Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer
CLARKE, N. W., McCLURE, J., & GEORGE, N. J. R. (1991) · British Journal of Urology · doi:10.1111/j.1464-410x.1991.tb15260.x · Cited by 192 · cited 1×
“Osteoclast number and activity are increased in bone metastases, in bone adjacent to metastases, and in distant uninvolved bone (1, 2).”
BackgroundOEFELEIN, M. G., RICCHUITI, V., CONRAD, W., SEFTEL, A., BODNER, D., GOLDMAN, H., & RESNICK, M. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65661-3 · Cited by 188
Cited by
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Self-citationReview of Exercise Intervention Studies in Cancer Patients
Galvão, D. A., & Newton, R. U. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.085 · Cited by 578
Bone metastasis: the importance of the neighbourhood
Croucher, P. I., McDonald, M. M., & Martin, T. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.44 · Cited by 479
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Metadata
- Authors
- Michaelson, M. D., Marujo, R. M., & Smith, M. R.
- Affiliations
- Massachusetts General Hospital (US)
- Venue
- Clinical Cancer Research
- Published
- 2004-04-15
- Volume
- 10
- Issue
- 8
- Pages
- 2705-2708
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2111758990
- Cited by
- 60
- References
- 17
- Citations by year
- 2026: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 4 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 5
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (1K12CA87723-01, K12CA087723)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- androgen deprivation therapy, metastatic prostate cancer, osteoclast activity, bone-specific alkaline phosphatase, N-telopeptide, bone turnover markers, bone metastasis, castration, osteoblast activity
- MeSH terms
- Aged, Alkaline Phosphatase, Androgen Antagonists, Bone and Bones, Collagen, Humans, Male, Middle Aged, Neoplasm Metastasis, Osteoblasts, Osteoclasts, Peptides, Prostatic Neoplasms, Collagen Type I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-03-0735
- The paper
- Michaelson, M. D., Marujo, R. M., & Smith, M. R. (2004). Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-03-0735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.